期刊文献+

沙格列汀与二甲双胍治疗初诊伴超重的2型糖尿病患者疗效对比研究 被引量:9

Comparative study of newly diagnosed type 2 diabetes patients with overweight treated by saxagliptin and metformin
下载PDF
导出
摘要 目的比较沙格列汀与二甲双胍治疗初诊伴超重的2型糖尿病患者的疗效。方法选取合并超重的初诊2型糖尿病患者124例,随机分为二甲双胍治疗组(62例)和沙格列汀治疗组(62例),分别在生活方式干预基础上给予常规沙格列汀与二甲双胍治疗,随访12w,检测治疗前后血压、血糖、糖化血红蛋白、血脂、胰岛素等指标,并比较两组的治疗效果。结果两组治疗后血糖均较治疗前明显下降,差异有统计学意义(P<0.05);沙格列汀组空腹血糖与糖化血红蛋白下降程度与二甲双胍组比较,差异无统计学意义(P>0.05),沙格列汀组餐后血糖低于二甲双胍组,差异有统计学意义(P<0.05),两组患者血压、血脂等指标均较治疗前有所好转,但组间差异无统计学意义(P>0.05)。结论对于合并超重的初诊的2型糖尿病患者,沙格列汀和二甲双胍治疗效果相当。 Objective To compare the efficacy of saxagliptin and metformin to newly diagnosed type 2 diabetes with overweight. Methods 124 cases who were newly diagnosed type 2 diabetic patients with overweight were divided into two groups and given saxagliptin and metformin respectively for 12 weeks based on lifestyle intervention. Then compare the treatment effect between two groups based on the detection of Blood pressure, blood glucose, glycated hemoglobin, lipids, insulin and other indicators of everyone before and after treatment. Results Blood glucose were significantly reduced after any kind of drugs treat- ment, and the difference was statistically significant (P〈0.05);The postprandial blood glucose of Saxa- gliptin group is lower than metformin group (P〈0.05), while, there was no statistical significance in the comparison between the decrease of fasting blood glucose and glycosylated hemoglobin of Saxagliptin group and metformin group (P〉0.05); blood pressure, lipids and other indicators were improved com pared with before treatment in two groups , but no significant difference between two groups (P〉0.05) Conclusion For the cases combined overweight with newly diagnosed type 2 diabetes , the effect of saxa gliptin and metformin treatment is equal.
作者 张明涛 张红
出处 《新疆医科大学学报》 CAS 2014年第4期473-475,共3页 Journal of Xinjiang Medical University
基金 克拉玛依科学技术局技术研发项目(SK2011-34)
关键词 沙格列汀 二甲双胍 2型糖尿病 saxagliptin metformin type 2 diabetes
  • 相关文献

参考文献9

  • 1Bolen S, Feldman L, Vassy J, et al. Systematic review:corn parative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med, 2007, 147(6) :386-399.
  • 2刘烨,洪天配.DPP-4抑制剂与二甲双胍联合治疗的合理性及其研究证据[J].中华内分泌代谢杂志,2012,28(12):1033-1035. 被引量:18
  • 3Drouin P, Blickle JF, Charbonnel B, et al. Diagnosis and clas- sification of diabetes mellitus:the new criteria. Diabetes Metab, 1999, (25):72-83.
  • 4曾龙驿.维格列汀与二甲双胍联合治疗2型糖尿病之疗效分析[J].中华糖尿病杂志,2012,4(1):58-59. 被引量:16
  • 5Park H, Park C, Kim Y, et al. Efficacy and safety of dipepti dyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. Ann Pharmacother, 2012, 46(11):1453-1469.
  • 6陈丹燕,邓华聪.二肽基肽酶-Ⅳ抑制剂治疗2型糖尿病研究进展[J].国际内分泌代谢杂志,2009,29(1):32-35. 被引量:4
  • 7Karagiannis T, Paschos P, Paletas K, et al. Dipeptidyl pepli- dase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting:systematic review and meta-analysis [J]. BMJ, 2012, 344(3):e1369.
  • 8Lasserson D, Mant J. The role of dipeptidyl peptidase 4 inhibi tors. BMJ, 2012, 344(3):e1213.
  • 9Mikhail N.Safety of dipeptidyl peptidase 4 inhibitors for treat- ment of type 2 diabetes [J ]. Curr Drug Saf, 2011, 6(5): 304-309.

二级参考文献65

  • 1Azuma K, Rodikova Z, Mancino J, et al. Measurements of islet function and glucose metabolism with the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab, 2008,93:459-464.
  • 2Drucker DJ,Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet ,2006,368 : 1696-1705.
  • 3Hansotia T, Drucker DJ. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice. Regul Pept,2005,128 : 125-134.
  • 4Ayala JE, Bracy DP, Hansotia T, et al. Insulin action in the double incretin receptor knockout mouse. Diabetes, 2008, 57: 288 -297.
  • 5Ahren B,Hughes TE. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate eyclase-activating polypeptide, and gastrin-releasing peptide in mice. Endocrinology, 2005, 146: 2055 -2059.
  • 6Green BD, Irwin N, Flatt PR, et al. Pituitary adenylate cyclase-activating peptide (PACAP) :assessment of dipeptidyl peptidase Ⅳ degradation, insulin-releasing activity and antidiabetic potential Peptides, 2006,27 : 1349 - 1358.
  • 7Lamont B J, Drueker DJ. Differential antidiabetic effieacy of incretin agonists versus DPP-4 inhibition in high fat fed mice. Diabetes,2008,57 : 190-198.
  • 8Kuo LE ,Kitlinska JB ,Tilan .IU ,et al. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obcsit3, and metabolic syndrome. Nat Med,2007,13 : 803-811.
  • 9Green BD, Flatt PR, Bailey C J, et al. Dipeptidyl peptidase Ⅳ (DPP Ⅳ) inhibitors:A newly emerging drug class for the treatment of type 2 diabetes. Diab Vasc Dis Bes,2006,3 : 159-165.
  • 10Pospisilik jA, Martin J, Doty T,et al. Dipeptidyl peptidase Ⅳ inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes, 2003, 52: 741-750.

共引文献33

同被引文献41

引证文献9

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部